Reference | Country | Study design | Age (y)a | Diagnosis | Dosing | Sampling and analysis | bFollow-up (months) |
---|---|---|---|---|---|---|---|
Faraci (2017) [20] | Italy | retrospective | 2.9 (1.56–9.9) | NR | iv 0.8–1.2 mg/kg (q6h*4d); po 16 mg/kg or 480 mg/m2(q6h*4d) | 0,1, 2, 4, and 6 h after the start of infusion/HPLC-UV | 48.8 (0.4–139) |
Okamoto (2014) [23] | Japan | prospective | 6 (0.5–17) | AML (10); ALL (4); CML (2); JMML (5); Others (4) | iv 0.8–1.2 mg/kg (q6h*4d) | 1, 2, 2.25, 2.5, 3, and 6 h after the start of infusion/GC-MSD 1,2, 2.5, and 6 h after dose 9; 0, 2.5and 6 h after dose 13/GC-MS | ≥3.33 |
Maheshwari (2013) [13] | USA | prospective | 6.2 (1.2–15.5) | SCD | iv1.0 mg/kg or 0.8 mg/kg (q6h*4d) | 2, 2.25,2.5,3, 4, 5 and 6 h after the start of infusion/GC-MS | 36 (14.4–72) |
Veal (2012) [24] | UK | prospective | mean3.6 | NB | po 1.45 or 1.55 mg/kg (q6h*4d) iv 0.8–1.2 mg/kg (q6h*4d) | 1, 2.25, 2.5, 3 and 6 h after the start of infusion for doses 1 and 9; 0, 2.5, 6 h after the start of infusion for dose 13/GC-MS | ≥60 |
cMichel (2011) [14] | France | prospective | – | AML (17); SCD (7); CML (3); NB (27); others (10) | iv 0.8–1.2 mg/kg (q6h*4d) | NR/GC-MS | – |
dWall (2009) [15] | USA | prospective | – | AML (8); JMML (2); MDS (2); β-thalassemia (3); Others (9) | iv1.0 mg/kg or 0.8 mg/kg (q6h*4d) | 2,3,4,5,6 h after the start of infusion for doses 1 and 9;2 and 6 h after the start of infusion for doses 13 /GC-MS | 10.2 (2–23.2) |
Vassal (2008) [16] | France | prospective | 5.6 (0.3–17.2) | NB (24); AML (14); SCD (5); EWS (3); CML (3); Others (6) | iv 0.8–1.2 mg/kg (q6h*4d) | 0, 1, 2, 2.25, 2.5, 3 and 6 h after the start of infusion for doses 1 and 9;0, 2.25 and 6 h after the start of infusion for doses13/GC-MS | NR |
eBouligand (2003) [25] | France | retrospective | 4.4 (1.1–15.7) | malignant solid tumor | po 37.5 mg/m 2 (q6h*4d) | 0.5, 2 and 6 h after the start of infusion for dose 1; 6 h after the start of infusion for dose 2, 3, 4, 12,13/GC-MS | NR |
Reference | Country | Study design | Age (y)a | Diagnosis | Dosing | Sampling and analysis | bFollow-up (months) |
fMcCune (2003) [2] | USA | retrospective | 6 (0.25–16) | AML (19); MDS (7); SCID (5); others (22) | po total dose 11–28 mg/kg (q6h*4d) | 0, 1, 2, 3, 4, 6 h after the start of infusion for dose 5 and dose 9/GC-MS | NR |
fBolinger (2001) [26] | USA | prospective | (0.6–17.1) | AML (6); CML (5); β-thalassemia (3); AA (4); SCD (4); others (10) | po total dose 10.9–28.9 mg/kg | 0.5, 1, 2, 3, 4, 5, 6 h after the start of infusion for dose 1; 0, 0.5, 1, 2, 4, 6 h after the start of infusion for dose 5, 9 and 13/GC-MS | NR |
Bolinger (2000) [17] | USA | prospective | (0.6–18) | β-thalassemia (10); AML (9); others (13) | po total dose 14–20 mg/kg | 0, 0.5, 1, 2, 3, 4, 5 and 6 h after the start of infusion for dose 1 and dose 13/GC-MS | NR |
Tran (2000) [29] | USA | prospective | 7.6 (0.8–18) | ALL (13); AML (7); MDS (3); CML (1); NHL (1) | po 40 mg/m2 | 0, 0.5, 1, 2, 4, 6 h after the start of infusion for dose 1, dose 5 and dose 9/HPLC-UV | 32 (11–52) |
VASSAL (1996) [27] | France | retrospective | 5.9 (1–15) | NB (28); Brain tumors (13); NHL (5); others (11) | po 1 mg/kg or 30–37.5 mg/m2 | 20 min, 40 min as well as 1, 1.5, 2, 3, 4, and 6 h after the start of infusion for dose 1, dose 5 and dose 9/GC-MS | NR |